Publication

Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy

Kahle, X. U., de Jesus, F. M. M., Glaudemans, A. W. J. M., Lub-de Hooge, M. N., Jorritsma-Smit, A., Plattel, W. J., van Meerten, T., Diepstra, A., van den Berg, A., Kwee, T. C., Noordzij, W., de Vries, E. G. E. & Nijland, M., Jun-2020, In : Lancet Haematology. 7, 6, p. E479-E489 11 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • Molecular imaging in lymphoma beyond 18F-FDG-PET_ understanding the biology and its implications for diagnostics and therapy

    Final publisher's version, 12 MB, PDF document

    Request copy

DOI

Mature lymphoproliferative diseases are a heterogeneous group of neoplasms arising from different stages of B-cell and T-cell development. With improved understanding of the molecular processes in lymphoma and novel treatment options, arises a growing need for the molecular characterisation of tumours. Molecular imaging with single-photon-emission CT and PET using specific radionuclide tracers can provide whole-body information to investigate cancer biology, to evaluate phenotypic heterogeneity, to identify resistance to targeted therapy, and to assess the biodistribution of drugs in patients. In this Review, we evaluate the existing literature on molecular imaging in lymphoma, other than F-18-fluordeoxyglucose molecular imaging. The aim is to examine the contribution of molecular imaging to the understanding of the biology of lymphoma and to discuss potential implications for the diagnostics and therapy of this disease. Finally, we discuss possible applications for molecular imaging of patients with lymphoma in the clinical context.

Original languageEnglish
Pages (from-to)E479-E489
Number of pages11
JournalLancet Haematology
Volume7
Issue number6
Publication statusPublished - Jun-2020

    Keywords

  • NON-HODGKINS-LYMPHOMA, POSITRON-EMISSION-TOMOGRAPHY, TREATMENT-INDUCED APOPTOSIS, B-CELL LYMPHOMA, BRENTUXIMAB VEDOTIN, MONOCLONAL-ANTIBODY, IBRITUMOMAB TIUXETAN, T-CELLS, PHASE-I, RADIOIMMUNOTHERAPY

ID: 126333451